Sareum (LON:SAR) Shares Down 7.6% – What’s Next?

Sareum Holdings plc (LON:SAR) shares dropped 7.6% during trading on Thursday . The stock traded as low as GBX 14.50 and last traded at GBX 15.25. Approximately 666,925 shares changed hands during trading, an increase of 179% from the average daily volume of 238,743 shares. The stock had previously closed at GBX 16.50.

Sareum Stock Down 7.6%

The firm has a market capitalization of £21.05 million, a P/E ratio of -4.24 and a beta of -1.08. The firm has a 50 day moving average of GBX 17.37 and a 200-day moving average of GBX 18.09.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.